Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
19.3M
-
Number of holders
-
199
-
Total 13F shares, excl. options
-
15.3M
-
Shares change
-
+468K
-
Total reported value, excl. options
-
$1.1B
-
Value change
-
+$33M
-
Put/Call ratio
-
0.83
-
Number of buys
-
99
-
Number of sells
-
-98
-
Price
-
$72.10
Significant Holders of LIGAND PHARMACEUTICALS INC - Common Stock (LGND) as of Q2 2023
237 filings reported holding LGND - LIGAND PHARMACEUTICALS INC - Common Stock as of Q2 2023.
LIGAND PHARMACEUTICALS INC - Common Stock (LGND) has 199 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 15.3M shares
of 19.3M outstanding shares and own 79.4% of the company stock.
Largest 10 shareholders include BlackRock Inc. (2.91M shares), VANGUARD GROUP INC (1.85M shares), JANUS HENDERSON GROUP PLC (1.34M shares), MACQUARIE GROUP LTD (837K shares), STATE STREET CORP (613K shares), DIMENSIONAL FUND ADVISORS LP (531K shares), VILLERE ST DENIS J & CO LLC (479K shares), Stephens Investment Management Group LLC (466K shares), Chicago Capital, LLC (424K shares), and abrdn plc (389K shares).
This table shows the top 199 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.